| Literature DB >> 35498942 |
Barnali Deb1, Sudhan Debnath2, Ankita Chakraborty1, Swapan Majumdar1.
Abstract
We report herein an operationally simple, efficient and versatile procedure for the synthesis of bis-indolylmethanes via the reaction of indoles with aldehydes or ketones in the presence of silica-supported ferric chloride under grindstone conditions. The prepared supported catalyst was characterized by SEM and EDX spectroscopy. The present protocol has several advantages such as shorter reaction time, high yield, avoidance of using harmful organic solvents during the reaction and tolerance of a wide range of functional groups. Molecular docking studies targeted toward the binding site of SARS-CoV-2 main protease (3CLpro or Mpro) enzymes were investigated with the synthesized bis-indoles. Our study revealed that some of the synthesized compounds have potentiality to inhibit the SARS-CoV-2 Mpro enzyme by interacting with key amino acid residues of the active sites via hydrophobic as well as hydrogen bonding interactions. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35498942 PMCID: PMC9041420 DOI: 10.1039/d1ra05679d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Bis(indolyl) methane and some naturally occurring bis-indolylmethane alkaloids.
Scheme 1General strategy for the synthesis of BIMs under solvent-free SiO2-FeCl3 catalysis.
Fig. 2Characterisation of the SiO2-FeCl3 catalyst: [A] SEM images SiO2 of 230–400 mesh, [B] SEM images of freshly prepared SiO2-FeCl3, [C] six-month-old SiO2-FeCl3, [D] recycled SiO2-FeCl3 and [E] EDAX spectrum of SiO2-FeCl3 showing absorption peaks for Fe, Cl, Si and O.
Optimization of catalyst loading, effect of solvent and temperature on model reaction of BIM synthesis
|
| |||||
|---|---|---|---|---|---|
| Entry | Catalyst | Solvent | Temp (°C) | Time (min) | Yield |
| 1 | No | No | rt | 120 | NR |
| 2 | No | No | 80 | 15 | Mixture |
| 3 | SiO2 | No | 80 | 180 | 70 |
| 4 | FeCl3 | No | 80 | 30 | mixture |
| 5 | SiO2-FeCl3 (2 mol% FeCl3) | No | rt | 180 | 92 |
| 6 | SiO2-FeCl3 (2 mol%) | No | 80 | 5 | 96 |
| 7 | SiO2-FeCl3 (4 mol%) | No | 80 | 5 | 96 |
| 8 | SiO2-FeCl3 (1 mol%) | No | 80 | 20 | 92 |
| 9 | SiO2-FeCl3 | CH2Cl2 | rt | 15 | 84 |
| 10 | SiO2-FeCl3 | EtOH | rt | 90 | 87 |
| 11 | SiO2-KHSO4 | No | 80 | 10 | 65 |
| 12 | SiO2-HClO4 | No | 80 | 15 | 58 |
| 13 | SiO2-H2SO4 | No | 80 | 10 | 78 |
| 14 | Cu nano | No | 80 | 90 | 90 |
| 15 | Nano TS 1 | No | 80 | 40 | 50 |
| 16 | Amberlite IR 120H+ | No | 80 | 120 | 90 |
| 17 | SiO2-FeCl3 | No | 80 | 15 | 95 |
Isolated yield.
Calculated based on the amount of FeCl3 used during preparation.
Reaction in 10 mmol scale.
Fig. 3Scope of aldehydes and aliphatic/aromatic ketones.
Fig. 4Catalytic recyclability of SiO2-FeCl3 from the reaction between benzaldehyde and indole.
Fig. 5(a) Structure of the SARS-CoV-2 co-ligand (N3). (b) Structure of known inhibitors 5 and 6.
Fig. 6(a) 3D interactions of the co-ligand with active site amino acid residues of Mpro are depicted by PyMOL in the X-ray crystallographic protein-co-ligand complex of 6LU7. (b) Binding pose of known inhibitors 5 and 6 in the receptor-active site of SARS-CoV-2 Mpro is depicted in PyMOL [structures 5 and 6 (yellow) and co-ligand N3 (green)].
The binding affinity (kcal mol−1) was predicted by AutoDock Vina, binding energy (kcal mol−1) was predicted by AutoDock and interacting amino acid residues
| Compounds | Binding affinity | Binding energy |
| Interacting amino acid residues |
|---|---|---|---|---|
| Co-ligand (N3) | −6.6 | −7.35 | 4.07 | Hydrophobic: HIS-41, MET-49, LEU-27, PHE-140, LEU-141, ASN-142, CYS-145, HIS-163, HIS-164, MET-165, GLU-166, LEU-167, PRO-168, ARG-188, GLN-189; H-bonding: GLY-143 (2.97 Å) |
| 5 | −7.7 | −9.71 | 76.45 | Hydrophobic: THR-25, THR-26, MET-49, PHE-140, LEU-141, ASN-142, CYS-145, HIS-164, MET-165, PRO-168, ASP-187, THR-190; H-bonding: HIS-41 (3.14 Å), GLN-189 (3.11 Å) |
| 6 | −7.9 | −8.43 | 664.7 | Hydrophobic: HIS-41, MET-49, PHE-140, ASN-142, HIS-164, MET-165, GLU-166, LEU-167, PRO-168, ASP-187, ARG-188, GLN-189; H-bonding: LEU-141 (3.07 Å), GLY-143 (3.13, 3.15 Å), SER-144 (2.81 Å), CYS-145 (3.05 Å), HIS-163 (3.00 Å) |
| 1c | −7.8 | −9.05 | 232.93 | Hydrophobic: HIS-41, MET-49, PHE-140, LEU-141, CYS-145, HIS-164, MET-165, GLU-166, ASP-187, ARG-188, GLN-189 |
| 1e | −7.6 | −8.88 | 307.65 | Hydrophobic: HIS-41, MET-49, PHE-140, LEU-141, CYS-145, HIS-164, MET-165, GLU-166, ASP-187, ARG-188, GLN-189 |
| 1f | −7.9 | −8.58 | 515.25 | Hydrophobic: HIS-41, HIS-164, HIS-163, LEU-141, ASN-142, GLU-166, MET-165, GLN-189. H-bonding: CYS-145 (3.12), SER-144 (3.16, 2.81), ASN-142 (3.06, 3.18 Å) |
| 1g | −7.3 | −9.29 | 154.54 | Hydrophobic: PHE-140, LEU-141, ASN-142, GLY-143, SER-144, CYS-145, HIS-163, HIS-164, MET-165, GLU-166, ARG-188, GLN-189 |
| 1l | −7.3 | −8.32 | 794.7 | Hydrophobic: MET-49, PHE-140, ASN-142, CYS-145, HIS-164, MET-165, GLU-166, ARG-188, GLN-189 |
| 1m | −6.7 | −8.31 | 813.9 | Hydrophobic: PHE-140, LEU-141, ASN-142, HIS-164, MET-165, GLU-166, GLN-189. H-bonding: HIS-163 (3.02 Å) |
| 1n | −7.9 | −9.13 | 203.59 | Hydrophobic: HIS-41, MET-49, PHE-140, LEU-141, ASN-142, CYS-145, HIS-164, MET-165, GLU-166, ASP-187, ARG-188, GLN-189 |
| 1r | −5.8 | −6.6 | 14.35 | Hydrophobic: THR-25, HIS-41, MET-49, PHE-140, LEU-141, ASN-142, CYS-145, HIS-163, HIS-164, MET-165, GLU-166, LEU-167, PRO-168, GLN-189 |
| 1s | −9.1 | −12.37 | 0.8513 | Hydrophobic: THR-199, TYR-237, ASN-238, TYR-239, LEU-271, MET-276, ALA-285, LEU-286, LEU-287; H-bonding: LEU-272 (3.00 Å), ASP-289 (2.85 Å) |
| 1t | −6.0 | −8.58 | 517.49 | Hydrophobic: HIS-41, MET-49, LEU-141, ASN-142, CYS-145, HIS-164, MET-165, GLU-166, ASP-187, ARG-188, GLN-189, THR-190; H-bonding: PHE-140 (3.24 Å) |
| 1w | −7.7 | −12.27 | 1.01 | Hydrophobic: TYR-239, LEU-286 THR-199; H-bonding: TYR-237 (3.14 Å), LEU-271 (3.27 Å), LEU-272 (2.91 Å), ALA-285 (2.92 Å), LEU-287 (2.80 Å) |
K i values expressed in μM.
Fig. 7Binding pose of the eleven compounds 1c, 1e, 1f, 1g, 1l, 1m, 1n, 1r and 1t (yellow) in the receptor-active site and 1s and 1w (yellow) in the allosteric site of SARS-CoV-2 Mpro is depicted using PyMOL. Compounds 1s and 1w were bounded in a different pocket unlike the co-ligand (green).
Fig. 8Schematic of the 2D interactions made by synthesized compounds (1c, 1e, 1f, 1g, 1l, 1m, 1n, 1r, 1s, 1t and 1w), coligand (N3), and known inhibitors 5 and 6 with SARS-CoV-2 Mpro receptor upon analysis using LigPlot. Compounds are represented as colored (carbon atom black, bonds purple, nitrogen blue, and oxygen red) and hydrogen bonds are displayed in green dotted lines, red stellations represents hydrophobic interactions and residues of proteins are shown in black color.